Update in Antiepidermal Growth Factor Receptor Therapy in the Management of Metastatic Colorectal Cancer

Table 2

Nonstatistical comparison of the results of the BOND-2 [23] and BOND-1 study [1].

BOND2	BOND2		BOND1	BOND1
Cetuximab, irinotecan, and bevacizumab	Cetuximab and bevacizumab		Cetuximab and irinotecan	Cetuximab alone
No. of Patients	43	40	218	111
Prior treatment with oxaliplatin (%)	87	89	62	64
Response rates (%)	37	20	23	11
Time to progression (months)	7.3	4.9	4.1	1.5
Median overall survival (months)	14.5	11.4	8.6	6.9